FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	
-------------	------	-------	--

STATEMENT	OF CHANGES	S IN BENEFICIAL	<b>OWNERSHIP</b>

or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL		
OMB Number:	3235-0287	
Estimated average burden		
hours per response:	0.5	

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b) Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer 1. Name and Address of Reporting Person (Check all applicable) **IONIS PHARMACEUTICALS INC** [ IONS Diaz Allene M. X Director 10% Owner Officer (give title Other (specify (Middle) below) below) (Last) (First) 3. Date of Earliest Transaction (Month/Day/Year) 07/15/2021 2855 GAZELLE COURT 4. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable (Street) Line) **CARLSBAD** 92010 Form filed by One Reporting Person CA Form filed by More than One Reporting (Citv) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 1. Title of Security (Instr. 3) 2. Transaction 2A. Deemed 5. Amount of 6. Ownership 7. Nature (Month/Day/Year) Beneficially if any Code (Instr. 5) (D) or Indirect Beneficial (Month/Day/Year) 8) Owned Following (I) (Instr. 4) Ownership (Instr. 4) (A) or (D) Transaction(s) Price Code Amount (Instr. 3 and 4) Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 8. Price of 1. Title of Derivative 11. Nature of Indirect 3. Transaction 3A. Deemed 5. Number 6. Date Exercisable and 7. Title and 9. Number of 10. Conversion Execution Date Transaction **Expiration Date** Ownership Amount of Derivative derivative (Month/Day/Year) Derivative Security or Exercise Code (Instr. (Month/Day/Year) Securities Security Securities Form: Beneficial (Instr. 3) Underlying Derivative Security Price of (Month/Day/Year) (Instr. 5) Beneficially Direct (D) Acquired (A) or Derivative Owned (Instr. 4) or Indirect Following (I) (Instr. 4) Security (Instr. 3 and 4) Disposed of (D) (Instr. 3, 4 Reported Transaction(s) (Instr. 4) and 5) Amount Date Expiration Code (A) (D) Exercisable Title Shares

## **Explanation of Responses**

**\$0.0**<sup>(1)</sup>

Restricted

1. Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.

Α

8,000

07/15/2021

2. Grant of July 15, 2021 to reporting person of Restricted Stock Unit award under the Amended and Restated Ionis Pharmaceuticals, Inc. 2002 Non-Employee Directors' Stock Option Plan. These Restricted Stock Units vest 100% on either the first anniversary of the date of grant or the next regularly scheduled annual meeting of stockholders of the Company, whichever occurs earlier, and will be delivered to the reporting person on the July 15th following the vesting date. The Restricted Stock Unit is vested as to 0 shares on July 15, 2021.

By: Patrick R. O'Neil, attorneyin-fact For: Allene M. Diaz

\$0.0

\*\* Signature of Reporting Person

8,000

Commo

Stock

(2)

8,000

D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

07/15/2021

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.